One Team.
One Mission.
We're on a mission to close a dangerous gap in ICU care—where aspiration pneumonia is common, deadly, and often detected too late.
Our Technology
Our team came together with a shared goal: to create a better way to detect aspiration risk before it becomes a life-threatening condition. The result is a novel, wearable technology that aims to give ICU teams continuous, predictive insight into their patients’ respiratory vulnerability—without invasive procedures or guesswork.
How It Works
Aspira is developing the first non-invasive wearable that continuously monitors aspiration risk in real time. Unlike outdated point-in-time assessments, Aspira offers continuous visibility into physiologic changes and delivers timely alerts to enable earlier clinical intervention.
The Aspira System features a low-cost, disposable patch that integrates easily into ICU workflows, bringing next-generation precision to one of critical care’s most dangerous and under-monitored complications. Ultimately, Aspira will enable a shift from reactive to proactive care resulting in improved outcomes for ICU patients.
First non-invasive, real-time gastric distension monitor for aspiration risk
Continuous monitoring vs. point-in-time assessments
Provides early notification for proactive clinical intervention
Low-cost, disposable wearable for widespread ICU adoption
Team
Zaffer Syed
CEO
Todd Rosengart, MD, FACS President & CMO
Joseph Petrosino, PhD
Board Member
Advisors
Dave Hughes, PhD
Ultrasound R&D
Tom Wilmering
Medical Device R&D
Allison Komiyama, PhD, RAC
Regulatory
Elizabeth Pash, PhD, MS, RDN
Medical Affairs